Bing

SEARCH HISTORY

Shares should continue to trade down, and we would not be looking to buy UTHR until the generic risk is fully priced into the stock, which we calculate to be in the high $30 range. You should assume that as of the publication date of any report or letter ...
Reuters · 10/24/2012
Some exciting biotech stocks work with stem cells ... leverages his deep understanding of the stem cell space to uncover viable therapies that double as excellent business models. In this interview with The Life Sciences Report, Kolbert guides investors ...
Kaptiall WIre · 12/19/2013
Today we'll look at United Therapeutics (UTHR), which develops therapies to treat pulmonary ... But with a strong 29% ... IBD Stock Analysis is a subscriber feature. Take a free trial now to get instant access.
Investor's Business Daily · 12/11/2014
I own a pair of biotech stocks. Gilead Sciences Inc. (GILD) sells for only 13 times earnings, and I recommend it at current prices. United Therapeutics Corp. (UTHR) has more than doubled since I bought it. It now sells for 50 times recent earnings ...
PITTSBURGH TRIBUNE-REVIEW · 6/9/2015
For an enhanced sector portfolio that enlists some top-ranked stocks (instead of ETFs) from within the top-ranked sectors, some long ideas from Healthcare, Technology, and Financial sectors include United Therapeutics (UTHR), Celgene (CELG), NICE …
istock Analyst · 4/7/2015
--(BUSINESS WIRE)--Sabrient Systems ... of +10%. The stock picks for 2012 include: Seagate Technology (STX), Western Refining, Inc. (WNR), Ocwen Financial Corp. (OCN), Watson Pharmaceutical (WPI), United Therapeutics Company (UTHR), Cloud …
Business Wire · 1/6/2012
Investors in health-care stocks have reason to feel ill ... Its largest recent purchase is United Therapeutics (UTHR), which is developing an oral formulation of its pulmonary arterial hypertension (PAH) drug Remodulin, whose three current delivery ...
Businessweek · 1/13/2011
Anheuser-Busch (NYSE: BUD): Goldman Sachs slashes the brewing stock to Sell from Neutral ... Shares are pulled from Credit Suisse's US Focus List. United Therapeutics (UTHR): JPMorgan moves the equity to Underweight from Equal Weight.
Minyanville · ByJustin Sharon · 10/24/2012
And his stock gains since 2009 run into the hundreds of millions ... Certainly not the patient advocates who protest Gilead's aggressively high prices. Or United Therapeutics ($UTHR), which gave CEO Martine Rothblatt a $36 million equity award in 2013 ...
FiercePharma · ByTracy Staton · 3/30/2015
Biotechnology stocks are posting particularly strong gains, resulting in 2.4 percent jump by the NYSE Arca Biotechnology Index. With the gain, the index has reached a new record intraday high. United Therapeutics (UTHR ... hovering firmly in positive ...
Finanznachrichten · 3/16/2015